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Abstract
Nontuberculosis mycobacteria (NTM) are ubiquitous in nature and opportunistically 
infect different animals, including humans. Currently, NTM is emerging as an important 
cause of pulmonary infection among both immunocompromised and immunocompe-
tent persons worldwide. The clinical relevance of pulmonary NTM varies among species 
while showing geographical heterogeneity in distribution as well as pathogenicity. The 
outcome of the respiratory NTM disease is a consequence of a complex interplay between 
microbial factors and host susceptibility. Furthermore, HIV infection, cystic fibrosis, can-
cer, underlying chronic lung disease and history of tuberculosis (TB) may be associated 
as risk factors for active nontuberculosis pulmonary diseases (NTMPD). The diagnosis of 
NTMPD requires the presence of symptoms, radiographic evidences, microscopic obser-
vations and definitive laboratory diagnostics. Lung infections resulted from a clinically 
significant NTM species should be treated with appropriate antimicrobial regimen.
Keywords: nontuberculosis mycobacteria, NTM, lung infections, NTM diagnosis,  
NTM infection
1. Introduction to genus Mycobacterium
The genus Mycobacterium was first proposed in 1896 by Lehmann and Neumann [1]. 
Currently, it contains about 160 species and it is likely that more will be discovered with 
recently developed more precise species identification techniques [2, 3]. Most species exist 
as free-living saprophytes and only minorities are successful as pathogens of higher verte-
brates. The host-dependent mycobacteria are capable of reproducing in vitro. In contrast, 
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M. leprae and M. lepraemurium are uncultivable and require the intracellular milieu for 
survival and propagation [4].
The obligatory causative agents of the genus Mycobacterium, responsible for TB are classified 
into Mycobacterium tuberculosis complex (MTC). It comprises M. tuberculosis, M.bovis, M. afri-
canum, M. microti [5], M. canettii [6], M. caprae [7], M. pinnipedii [8], M. mungi [9], M. orygis [10] 
and M. suricattae [11] species. M. tuberculosis, M. africanum, M. canettii and M. orygis cause TB 
primarily in human [4, 10], whereas M. bovis [12], M. microti [13], M. caprae [7] M. pinnipedii 
[8], M. mungi [9] and M. suricattae [11] infect cattle, domestic animals, goats, seals, mongooses 
and meerkats, respectively, and animal tuberculosis can also be zoonotic [14, 15]. However, 
geographical variation of the MTC species distribution has been identified. As an example, 
M. africanum is a common cause of human pulmonary TB (39%) as much as M. tuberculosis (55%) 
in West Africa [16]. In Ghana, 3% of pulmonary TB cases are represented by M. bovis, while 
20% are M. africanum and 73% are M. tuberculosis [17].
Other medically important mycobacteria such as M. avium, M. intracellulare complex, M. kan-
sasii, M. marinum, M. fortuitum, M. chelonae complex, M. abscessus and M. scrofulaceum are 
known as nontuberculosis mycobacteria (NTM) species or atypical mycobacteria or mycobac-
teria other than tuberculosis (MOTT). They are responsible for diseases including lymphad-
enitis in children, chronic pulmonary diseases, skin and soft-tissue diseases and infections of 
the skeletal system [18].
NTM are ubiquitous in nature and are widely distributed in water, soil and animals. Among 
prevailing NTM species, only a few species have a clinical impact on humans as opportu-
nistic pathogens [19]. M. avium complex (MAC), M. abscessus, M. kansasii, M. fortuitum, 
M. chelonae, M. szulgai, M. triviale and M. scrofulaceum are common NTM species that cause 
pulmonary diseases in human [20]. Additionally, M. riyadhense was recently proposed as a 
causative agent of pulmonary NTM disease [21]. However, NTM are increasingly recognized 
as a significant cause of chronic human pulmonary infections in both immunocompromised 
and immunocompetent patients [3].
In contrast to TB, diseases caused by NTM have varied clinical manifestations, triggering a 
wide spectrum of infections with generally low virulence than TB [20]. Patients with underly-
ing structural lung diseases such as chronic obstructive pulmonary diseases, cystic fibrosis, 
bronchiectasis, history of TB and chronic aspiration are more vulnerable to develop NTM 
lung disease [22]. Additionally, working in mining industry and advanced age are risk fac-
tors for NTM lung diseases. However, there is no evidence on animal-to-human (zoonosis) 
or human-to-human transmission of NTM, and human diseases are generally acquired from 
environmental exposure [22].
2. NTM species significant to lung diseases
NTM are emerging worldwide as significant causes of chronic pulmonary infection, while 
became a challenge for both clinicians and researchers in the past two to three decades [23]. 
However, isolation and discover of new NTM species from pulmonary clinical specimens 
have become frequent in the last years especially with the development of species identifica-
tion techniques such as sequencing of 16S ribosomal DNA (rDNA) [24].
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The pathogenicities of the different NTM species vary widely and show geographical hetero-
geneity. Commonly, most NTMPD infections are caused by the MAC, M. abscessus, M. kansasii 
[25, 26], M. fortuitum, M. chelonae [26], M. szulgai, M. gordonae, M. vaccae and M. smegmatis [20, 27].
MAC organisms are common in many environmental sites, including water and soil, and in 
animals as well as colonize in natural water sources, indoor water systems, pools and hot tubs 
[28]. Previously, MAC, a slow growing NTM species has been composed of M. avium and 
M. intracellulare but, with advance in genetic identification of species, MAC encompasses at least 
10 species, i.e. M. avium, M. intracellulare, M. arosiense, M. bouchedurhonense, M. chimaera, 
M. colombiense, M. marseillense, M. timonense, M. vulneris and M. yongonense, as well as 4 subspe-
cies, i.e. M. avium subsp. avium, M. avium subsp. silvaticum, M. avium subsp. hominissuis and 
M. avium subsp. paratuberculosis [21, 25, 29]. MAC may cause progressive parenchymal lung 
disease and bronchiectasis in patients, particularly in middle-aged and elderly women without 
underlying lung diseases [30]. Fibrocavitary lung disease caused by MAC may associated with 
large cavities specially in late 1940s and early 1950s years, males who have a history of cigarette 
smoking and excessive alcohol use. Untreated form of this disease is generally progressive to 
extensive cavitary lung destruction and respiratory failure within 1–2 years. MAC lung disease 
also presents with nodular and interstitial nodular infiltrates frequently involving the right 
middle lobe or lingual, called as nodular bronchiectasis or nodular bronchiectatic disease [31]. 
Particular MAC species may have varying degrees of virulence and classifying MAC isolates 
into species level is important for identification of risk of clinical relapse/reinfection [32, 33].
Tap water is likely the major reservoir for M. kansasii causing human pulmonary disease [34]. 
Genotypic studies in Netherland and France have shown that isolates recovered from the 
patients have similar genotype to isolates from drinking water source and the environment 
[35, 36]. DNA sequencing of M. kansasii has confirmed the presence of seven subspecies, 
which are related to human infections [37], while subtype 1 is the predominant in human 
lung infections [37–39]. Clinical symptoms of M. kansasii lung disease are generally identical 
to those associated with pulmonary TB. Chest radiographic abnormalities are also very simi-
lar to reactivation of pulmonary TB, including cavitary infiltrates with an upper lobe predi-
lection. Also, M. kansasii may show noncavitary or nodular/bronchiectatic lung disease [40], 
which is similar to clinical presentation of MAC.
Some studies have been strengthened that drinking water may be the source of infection of M. 
abscessus lung diseases [41]. The common clinical symptoms of M. abscessus and M. fortuitum 
infection are similar to other NTM respiratory pathogens, especially MAC, including cough 
and easy fatigability. Disease caused by M. genavense commonly has been recognized in 
acquired immunodeficiency syndrome (AIDS) patients, while observed also in HIV-negative 
patient with pulmonary nodules [42].
Although most NTM lung infections are caused by common organisms, other NTM species such as 
M. flavescens, M. mucogenicum [26, 43], M. colombiense, M. genavense, M. holsaticum, M. kumamotonense, 
M. lentiflavum, M. mantenii, M. marseillense, M. monacense, M. neoaurum, M. parascrofu-
laceum, M. phocaicum, M. saskatchewanense, M. seoulense, M. septicum, M. setense, M. shimoi-
dei, M. stomatepiae, M. szulgai, M. triplex [44], M. xenopi, M. malmoense, M. immunogenum [45], 
M. scrofulaceum, M. terrae complex, M. engbaeki, M. shimoidei, M. gilvum, M marinum, M. interjectum 
subspecies, M. heckeshornense, M. branderi and M. chromogen [24] may cause pulmonary disease in 
both immunocompetent and immunocompromised patients.
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Isolation of multiple NTM species from respiratory specimens has also been recorded. In 
Taiwan, two patients of 298, one had five isolates of MAC and one isolate of M. fortuitum, 
while another patient had 11 isolates of MAC and one isolate of M. gordonae [27]. Thus, the 
pathogenic significance of a NTM specimen must be determined in the context of a patient’s 
clinical presentation.
3. Prevalence and current epidemiology of pulmonary NTM disease
In Western societies, most laboratories report a dramatically greater prevalence of NTM than TB 
[46]. However, the prevalence of NTM pulmonary infections, which based on laboratory records, 
should be coupled with clinical characteristics [47] as only approximately half of people with pos-
itive NTM cultures fulfilled clinical criteria for active infection [48]. Studies form North America, 
Australia, South Korea, Japan and Taiwan have shown the continued increase in NTM prevalence 
since 2000. The annual prevalence in North America and Australia ranges from 3.2 to 9.8 per 
100,000 and is generally higher than in Europe. In Queensland, Australia, cases of pulmonary dis-
ease rose from 2.2 to 3.2 per 100,000 population [49] during 1999–2005. Furthermore, in Australia, 
the annual percent of NTM isolation has increased steadily every year, and the incidence rate of 
patients with NTM lung disease was 1.82 per 100,000 in 2006 and increased to 4.38 per 100,000 in 
2010 [50], while the same changed from 9.4 per 100,000 in 2009 to 36.1 per 100,000 in 2016 [51]. In 
Africa and the Middle East, prevalence of NTM ranges from 4 to 15% among suspected TB cases 
and 18% to 20% among suspected multidrug-resistant TB (MDR-TB) cases [52]. The prevalence 
rate of NTMPD in Germany was increased from 2.3 to 3.3 cases per 100,000 population from 2009 
to 2014, and this was strongly association with advanced age and chronic obstructive pulmonary 
disease [53]. The prevalence of NTM isolation approximately was doubled from 2005 (6%) to 
2013 (11%) in Hawaii, USA [26], while in Oregon, USA, the estimated prevalence of NTMPD was 
8.6 per 100,000 [48]. By 2014, in Japan, the incidence rate of NTMPD was 14.7 cases per 100,000 
person, which was ≈2.6 times higher than the same reported in 2007 and current incidence rate 
of NTMPD may exceed that of TB in Japan [48]. The general prevalence of NTM was 477 per 
100,000 in Zambia with the regional variation of rate of prevalence within the country [54]. In 
Korea, the rates of recovery of NTM from clinical specimens and the number of patients with 
NTM lung infections increased significantly between 2009 and 2015 [55].
While some species such as MAC and M. abscessus are commonly implicated worldwide, oth-
ers (e.g., M. malmoense, M. xenopi) are regionally important [23]. Generally, MAC is predomi-
nant in North America and East Asia, whereas M. kansasii, M. xenopi and M. malmoense are more 
common in Europe [52]. In Hawaii, USA, the most prevalent species was MAC, M. fortuitum 
group and M. abscessus [26]. Even though isolation of slowly growing mycobacteria (SGM) is 
frequent in most of the European and Western countries, rapidly growing mycobacteria (RGM) 
species such as M. fortuitum and M. abscessus are more prevalent in Gulf Cooperation Council 
(GCC) except in few countries [56]. As examples, M. fortuitum was the predominant course 
of NTM lung disease in Middle East during 1984–2014 [57]. Furthermore, M. fortuitum and 
M. abscessus are predominant in Saudi Arabia, while MAC is the most common species in 
Oman [56]. However, it has been observed in Saudi Arabia that rare species are going to be 
prominent, alarming diversity of clinically relevant NTM’s causing pulmonary infections [58].
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The most frequent NTM species were M. intracellulare followed by M. avium subspecies in 
South Africa by 2010 [59], while M. kansasii is the more frequently associated among defi-
nite or probable active TB patients. Also, M. avium-intracellulare complex was the prominent 
course of NTM lung infections in Greece during 2007–2013 [60].
Furthermore, clinical relevance of pulmonary NTM species shows not only the geographically 
heterogeneous but also the time-to-time variations. As examples, MAC was the main cause of 
pulmonary diseases in India during the period of 1971–2007 [20]. But, according to the recent 
publications, M. abscessus was the predominate species followed by M. intracellulare [61, 62] in 
India, even both of the species were not recorded till 2007 [20] (Table 1). M. intracellulare followed 
by M. kansasii were most common NTM species related to the NTMPD in China from 2004 to 
2009 [63] and it changed in 2010–2015 period, as M. kansasii was replaced by M. abscessus [64, 65]. 
Similar observation had been in Japan where, dramatic increases of pulmonary M. abscessus 
incidence had been occurred [48] comparative to period of 2001–2007.
Furthermore, in Korea, M. intracellulare followed by M. avium was predominate species dur-
ing 2009–2015, while it was M. avium followed by M. abscessus in earlier (Table 1) [55].
4. Host-pathogen interactions
Unlike TB, the mode of transmission of NTM to humans has not been defined. Bathroom 
showers have been implicated as a primary source of exposure to aerosolized NTM. Even 
though animals are potential reservoir for NTM infections, zoonosis is not properly  evident 
yet. However, drinking untreated water and living in close contact with cattle or other 
domestic animals may lead of infection in human [66]. In USA, NTM diseases are more 
Country 
(no. of 
infections 
tested)
NTM species (%)
M. 
abscessus
M. 
avium
M. 
chelonae
M. 
fortuitum
M. 
gordonae
M. 
kansasii
M. 
triviale
M. 
scrofulaceum
M. 
szulgai
India (15) – – – 40 – 33 20 – 7
Hong Kong 
(28)
– 54 14 – 4 4 – – 4
South Korea 
(131)
39 50 2 3 – 4 – – 0
Japan (1064) – 81 0.6 2 – 14 – – 0.5
Thailand 
(132)
– 43 5 5 – 17 – 8 –
Singapore 
(15)
– 60 7 – – 27 – 7 –
Taiwan (302) 19 43 10 10 – 9 – –
Table 1. NTM species causing pulmonary infections in Asian region during 1971–2007 [20].
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 associated with densely populated areas, suggesting the infective source as urban municipal 
water supply [67], while Japan suggesting the soil as the source for more patients who were 
farmers and gardeners [68]. Furthermore, characteristic gradient clustering of the ratios of 
M. avium and M. intracellulare has been observed in Japan, suggesting that environmental 
factors strongly affect the epidemiology of NTMPD [69].
The outcome of the respiratory NTM disease is a result of a complex interplay between microbial 
factors like particle size, number of organisms and duration of contact and host susceptibility fac-
tors such as immunity, genetic background, lung damages and chronic lung disease. The clinical 
presentation of NTM lung infections may be varied, including hypersensitivity pneumonitis (HP)-
like granulomatous lung disease, cavitary (TB-like) disease and nodular bronchiectasis. A hyper-
sensitivity pneumonitis (HP)-like granulomatous lung disease, with nontuberculous mycobacteria 
can be triggered by inhalation of NTM with hot water aerosols (hot-tub lung) from sources such 
as hot tubs/spas, showers and indoor swimming pools. This may have been the primary source of 
MAC infections in middle-aged women with subacute presentation of respiratory complaints and 
HIV patients in the United States [70]. While MAC is the most common NTM causing “hot tub 
lung,” M. fortuitum has also been rarely implicated [71]. Physicians need to be alerted to the pos-
sibility of hot tub lung being caused by various NTM species other than MAC. Furthermore, a case 
study has been confirmed M. gordonae as a potential pathogen in humidifier lungs [72].
Rarely, with underlying lung disease or smoking or prior TB, cavitary disease could be caused 
by multiple NTM species especially by MAC. This condition is different from the typical pre-
sentation of MAC pulmonary infections as they may have upper lobe cavity, as well as TB-like 
symptoms [73, 74]. Nodular bronchiectasis, which is often present with older nonsmoking 
female, is associated mostly with MAC. Sometimes, mixed infections of MAC and M. abscessus 
may lead to nodular bronchiectasis [75, 76]. In really, solitary pulmonary nodules (SPN) due to 
MAC infection also have been identified in some studies [74, 77, 78]. However, clinical outcome 
of the NTM diseases basically depends on the interactions between NTM and the host (Figure 1).
4.1. Host factors
Immunosuppressed hosts who may be associated with immunosuppressive HIV infection, 
hematological and lymphoproliferative malignancy, stem cell and solid organ transplant and 
 inflammatory disorders treated with biologicals are highly vulnerable for pulmonary infections 
caused by M. avium and other nontuberculous species. Defense against Mycobacterium species 
Figure 1. Interactions between NTM and the host that determine the clinical outcome.
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is mediated by mononuclear phagocytes’ ability to kill mycobacteria and secrete interleu-
kin-12 (IL-12), augmented by interferon-gamma (IFNγ) secreting lymphocytes such as CD4+T 
cells. Human natural killer cells (NK) are important in host defense against Mycobacterium as 
it secretes cytokines that induce macrophages to inhibit the growth of bacteria within mac-
rophages [79, 80]. Cytokines that induce IL-32 (newly described pro-inflammatory cytokine), 
such as interferon-gamma, IL-18, IL-12, granulocyte-macrophage colony-stimulating factor 
and tumor necrosis factor-alpha, have considerable importance in mycobacterial immunity 
[81]. The alliance formed between IL-12 and IFN-gamma is essential for protective immunity 
against mycobacteria in human [82]. Therefore, genetic deficiencies in immunity mediated by 
IL-12 or IFN-gamma are highly susceptible to mycobacteria NTM infections in both individu-
als and familial clusterings of disease [79, 83].
IL-32 is expressed in multiple cell types in the lungs but particularly in the airway epithe-
lial cells of patients with MAC pulmonary disease. Human airway epithelial cells (BEAS-2B) 
infected with M. avium produce IL-32 by a nuclear factor-kappa B-dependent mechanism. 
In both BEAS-2B cells and human monocyte-derived macrophages, exogenous IL-32 signifi-
cantly reduced the growth of intracellular M. avium by increased apoptosis of infected cells. 
Thus, IL-32 not only facilitates host defense against MAC organisms but may also contribute 
to the airway inflammation associated with MAC pulmonary disease [81].
In immune evasion mechanism of M. avium subsp. paratuberculosis (MAP), bacteria are sur-
vived in macrophages by activation of mitogen-activated protein kinase (MAPK) pathway 
that leads to inhibition of antimicrobicidal activity of macrophages and over expression of 
IL-10. High levels of IL-10 in paratuberculosis promote the survival of MAP by reducing 
bactericidal activity of defense cells. Therefore, the pathways involved in the upregulation 
of IL-10 such as MAPK can be vital for developing a therapeutic strategy for the control of 
paratuberculosis [84]. A monogenic disorders conferring susceptibility to NTM infection are 
called as Mendelian Susceptibility to Mycobacterial Disease (MSMD) conditions, which are 
extremely rare and predominantly affecting children. Genetic disorders, which affect the 
immune response to mycobacterial infection, are known to result from disorders in genes of 
ISG15, IL-12B, IL12RB1, IFNGR1, IFNGR2, STAT1, IRF8, ISG-15, GATA2, NADPH and oxi-
dase complex subunit genes such as CYBB [85].
Diseases and therapies that reduce cell-mediated immunity increase the risk of NTM disease. 
Acquired immunodeficiency virus (AIDS), cancer and organ transplants have been associated 
with NTM disease. The use of immunosuppressive drugs, including anti-TNF biologics, is also 
a risk factor for NTMPD [86]. NTM are often found in sputum cultures of patients with cystic 
fibrosis as they undergo lung transplantation followed by immunosuppressive medications. 
Therefore, effective medical treatment may need to control NTM after lung transplantation. 
The post-transplant infections can be associated with M. abscessus, which not affect for the sur-
vival of the patient in pre-transplantation stage. Therefore, sputum culture positivity for NTM 
before lung transplantation should not preclude transplantation, but should be treated in order 
to minimize the risk for recurrence after transplantation [87]. There is a possibility of co-existing 
pulmonary NTM infection in patients with lung cancer and disseminated NTM infection in 
patients with hematologic cancer [88, 89]. A study has suggested that anti-NTM therapy should 
be introduced only with worsening of symptoms under careful consideration as anti-NTM 
treatment is long and anti-mycobacterial drugs have extensive effects on anti-cancer drugs [90]. 
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Also female sex, age, post-menopausal waning of endogenous estrogen levels, coeliac disease 
and exposure to use of dietary phytoestrogens can be risk factors for NTM lung diseases [91] 
while oral corticosteroids treatment in rheumatoid arthritis patients is also a comorbidity of 
NTM disease [92]. However, another study has showed that bronchiectasis and NTM lung dis-
ease are risk factors for breast cancer in women, and this phenomenon will open a new pathway 
for investigation of common pathophysiologic links of NTMPD [93].
4.2. Microbial factors
Aside from host factors, microbial factors such as virulence and microbial dose of exposed 
would be considerable factors for progression of NTM lung diseases. The critical exposure 
dose and relationship between quantitative mycobacterial exposure and disease are yet to be 
known. However, it may vary with the host susceptibility. Although exposure is common, 
disease is unusual, as most of NTM species are nonpathogenic and pathogenicities are varied 
according to the NTM species. Only few are highly pathogenic in human in descending order 
of pathogenicity, M. malmoense, M. szulgai, M. kansasii, M. abscessus, M. Xenopi, M. avium and 
M. simiae/M. chelonae and M. intracellulare. Even though MAC account for the plurality of 
pulmonary isolates as well as disease worldwide, the clinical relevance of NTM isolation from 
respiratory specimens appears to vary by geographic region, presumably due to variability in 
both environmental microbial distribution and the prevalence of host risk factors [23].
5. Diagnosis of NTM lung infections
Unlike TB, the isolation of NTM in pulmonary specimens does not equate with disease. The 
guidelines published in 2007 by American Thoracic Society (ATS) and the Infectious Diseases 
Society of America (IDSA) (ATS/IDSA) have specified that both clinical and microbiologic 
criteria must be met for the confirmation of diagnosis of pulmonary NTM disease [22]. Also, 
correct species identification is vital as NTM species differ in their clinical relevance. Correct 
diagnosis and choice of treatment regimen are needed as to prevent misdiagnosis, which 
direct chronic disease, antimicrobial resistance and death [94]. However, identification of all 
clinically obtained NTM isolates, especially from sputum, may not be needed. For instance, 
the exact identification of a pigmented rapidly growing mycobacteria isolated in low num-
bers from only one of multiple sputum specimens collected from patient undergoing therapy 
for MAC lung disease may not be necessary as it would not likely be clinically significant [22]. 
The diagnosis requires the presence of symptoms, radiographic abnormalities or chest high 
resolution computed tomography (HRCT) scan in the absence of cavitations, three or more 
sputum specimens for acid fast bacilli (AFB) analysis and exclusion of other disorders such as 
TB and lung malignancy. According to the ATS/IDSA guidelines, the criteria apply for defini-
tive diagnosing of nontuberculous mycobacterial lung disease is following [22].
Clinical (both required)
1. Pulmonary symptoms, nodular or cavitary opacities on chest radiograph or an (HRCT) 
scan that shows multifocal bronchiectasis with multiple small nodules.
2. Appropriate exclusion of other diagnoses.
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Microbiologic.
1. Positive culture results from at least two separate expectorated sputum samples. (If the 
results from the initial sputum samples are nondiagnostic, consider repeat sputum AFB 
smears and cultures.) (or)
2. Positive culture results from at least one bronchial wash or lavage (or)
3. Transbronchial or other lung biopsy with mycobacterial histopathologic features (granu-
lomatous inflammation or AFB) and positive culture for NTM or biopsy showing myco-
bacterial histopathologic features (granulomatous inflammation or AFB) and one or more 
sputum or bronchial washings that are culture positive for NTM.
4. Expert consultation should be obtained when NTM are recovered that are either infre-
quently encountered or that usually represent environmental contamination.
5. Patients who are suspected of having NTM lung disease but who do not meet the diagnos-
tic criteria should be followed until the diagnosis is firmly established or excluded.
6. Making the diagnosis of NTM lung disease does not, perse, necessitate the institution of 
therapy, which is a decision based on potential risks and benefits of therapy for individual 
patients.
5.1. Clinical and radiographic based diagnosis
Delaying of diagnosis of NTM lung diseases is frequent due to the slow growing rate, misdi-
agnosed as TB or other AFB-positive bacilli and low index of clinical suspicion. The clinical 
symptoms, such as chronic cough, increased sputum production, dyspnea, low-grade fever, 
malaise and weight loss, are often nonspecific and overlapping clinical characteristics with 
pulmonary TB [95].
Radiological imaging and observing of radiological patterns, including miliary pulmonary 
pattern, nodular lesions, cavitary lesions, pleural effusion, abdominal adenopathy and splenic 
hypoechoic, is important when NTM lung disease is suspected in AIDS patients [96]. HRCT 
scanning allows early detection and better differentiation between colonization and invasive 
infection that are not visible on the chest X-ray [97]. In CT features; pleural effusion and nod-
ules are significantly more common in patients with pulmonary TB (PTB) while bronchiecta-
sis combined with cystic changes are significantly more common in patients with NTM lung 
infections [98]. Bronchiectasis in the right middle lobe or left lingual segment and thin-walled 
cavity with a diameter of more than 3 cm are the frequent chest CT features in patients with 
NTM-LD [99]. Furthermore, cavities associated with adjacent pleural thickening, ill-defined 
satellite tree-in-bud nodules or fewer noncavitary nodules in CT findings are highly sugges-
tive of NTM disease rather than TB [58, 100].
Also, NTM lung infection can present itself with different radiological patterns, while two 
main patterns, fibrocavitary form and nodular bronchiectatic form, have been observed fre-
quently [100]. The fibrocavitary form is usually characterized by upper lobe cavities with 
areas of increased opacity and with or without calcification (Figure 2) [98, 101].
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In the nodular bronchiectatic form: bilateral, multilobar bronchiectasis, especially in the mid-
dle and lower lung fields, with small nodules are the frequently observed chest CT features 
(Figure 3) [99, 101].
Even though there are no characteristic radiographic patterns for individual NTM species, 
centrilobular, peribronchovascular nodules, bronchiectasis, consolidation, tree-in-bud, pleu-
ral thickening and pleural adhesion are commonly observed CT findings in patients with 
MAC infection [102]. A recent study has shown that cavities are more common in patients 
with M. malmoense, while consolidations are mostly found among patients with an MAC and 
nodules are frequent in M. kansasii patients [103]. However, due to the presence of consider-
able overlap of the clinical symptoms and radiographic appearances of PTB and NTM lung 
diseases, the isolation and identification of causative organisms are mandatory for correct 
diagnosis of patients with AFB-positive sputum specimens [76].
Figure 2. CT of fibrocavitary form of M. intracellulare pulmonary disease with a large cavity in the right upper lobe [101].
Figure 3. CT of nodular bronchiectatic form of M. intracellulare pulmonary disease with severe bronchiectasis in the right 
middle lobe and the lingular segment of the left upper lobe [101].
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5.2. Laboratory diagnosis
The initial laboratory identification of the genus Mycobacterium can be made by microscopic 
observation for the presence of AFB. The definitive diagnosis demands the recovery of 
Mycobacterium species on a culture medium, followed by species identification tests. Although 
numerous novel, rapid and direct molecular methods have been developed, culture remains 
the gold standard for identification of Mycobacterium species from clinical specimens [104].
5.2.1. AFB smear microscopy
AFB staining, such as fluorochrome technique, Ziehl-Neelsen method or Kinyoun stain, 
which initially adopted for identification of Mycobacterium tuberculosis complex (MTBC), 
is satisfactory for NTM also. However, Smear microscopy cannot use for differentiation of 
MTBC form NTM, hence the presence of AFB can lead to a false-positive diagnosis of TB. The 
burden of organisms in clinical material is usually reflected by the number of organisms seen 
on stained smears. Since NTM are present in the environment, especially in water sources, the 
careful collection of high-quality respiratory specimens is necessary to avoid contamination. 
However, environmental contamination, which usually involves small numbers of organ-
isms, rarely results in a positive smear examination. Semi-quantitative analysis of smears can 
be useful for diagnostic purposes and fluorochrome smears are graded from 1 (1–9 organisms 
per 10 high-power fields) to 4 (90 organisms per high-power field) [101, 105, 106].
5.2.2. Mycobacterium culture and species identification by conventional methods
Isolation of Mycobacterium by culturing is a primary requirement in conventional species 
identification and indirect drug susceptibility testing of NTM. The general microbiological 
measures of growing clinical material on a selective or differential culture media and sub-
culturing to obtain pure cultures cannot be applied to Mycobacterium. Genus Mycobacterium 
will not grow on simple, chemically defined media and it requires special, enriched, selective 
media. Also, slow replication rate is a characteristic feature in culturing of Mycobacterium, 
hence culturing is time-consuming [107]. Generally, an AFB-positive sputum will require 
3 weeks for producing visible colonies of Mycobacterium on solid medium [4]. However, NTM 
species, such as M. fortuitum, M abscessus and M. chelonae, are considered as rapid growers as 
they grow into visible colonies within 3–5 days of incubation [19, 22].
As per ATS/IDSA guidelines, both solid and liquid cultures are required for NTM species iden-
tification. Even though mycobacteria produce more rapid cultures with high yield in broth 
media than those on solid media, solid cultures need to proceed simultaneously as they allow 
observing of colony morphology, growth rates and mixed infections (more than one mycobac-
terial species), which are important factors in identification of the NTM species. Also, broth 
media cultures alone may not be sufficient for better diagnosis of NTM species due to the bac-
terial overgrowth and high chance for the contaminations from other bacteria and fungus [22].
In conventional culture techniques, Lowenstein-Jensen (LJ) media and agar-based Middlebrook 
media (7H10 and 7H11) are used as the common solid media, while 7H9 medium used as the 
liquid/broth media. BACTEC MGIT 960 system is a fully automated, nonradiometric system 
that is suitable for the detection of growth of TB and other mycobacteria with the shorter 
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detection time ~2 weeks [108]. The recently introduced, microchannel electrical impedance 
spectroscopy (m-EIS) has ability to detect M. smegmatis with initial loads of 1000 CFU/ml 
within 20 h, while commercial BACTEC MGIT 960 system need 41.7 h for the same [109].
Species, such as M. haemophilum, M. genavense, M. avium subsp. paratuberculosis (formerly 
M. paratuberculosis) and M. ulcerans, are required special supplementation for recovery on 
culture media. M. haemophilum grows only on media supplemented with iron-containing 
compounds such as ferric ammonium citrate, hemin or hemoglobin [110]. M. genavense and 
M. avium subsp. paratuberculosis require mycobactin J, and M. ulcerans may be optimally 
recovered with egg yolk supplementation [22].
Microscopic observation of ZN-stained smear prepared from culture will provide evidence 
only for the presence of mycobacteria, purity of the culture and cord formation. These basic 
characters are not sufficient for definitive species level identification. The conventional taxo-
nomic differentiation of the genus Mycobacterium is based on phenotypic characters of the 
cultures and biochemical properties of bacteria. The characters of rapid growth, pigmentation 
(scotochromogens, photochromogens or nonchromogens), ability to grow in PNB incorpo-
rated media and creamy like watery colonies indicate the presence of NTM [107]. Several 
biochemical tests based on the properties of the genus Mycobacterium, including nitrate 
reductase, niacin production, catalase activity, production of arylsulfatase and urease, tween 
80 hydrolysis, growth in the presence of 5% NaCl and MacConkey agar without crystal violet 
and the use of mannitol, inositol and sorbitol, may adequate to identify majority of clinically 
relevant mycobacterial species [107].
5.2.3. Molecular-based identification methods
Biochemical analysis and phenotypic characters may occasionally fail to arrive at a defini-
tive identification. Because of differences in antimicrobial susceptibility at species level that 
determine treatment options, precise species identification of the NTM is required and only 
determination of merely as groups, such as M. chelonae (or/and M. abscessus) group, is not 
recommended [22]. To fulfill this requirement, rapid accurate and cost-effective molecular-
based techniques, both in-house and commercial kits, with satisfied sensitivity and specificity 
were developed during last years. Currently, molecular methods especially assays based on 
the principle of nucleic acid amplification which allows a speedy and precise identification of 
the Mycobacterium species in <24 h have been developed.
Real-time PCR, DNA sequencing, probe hybridization, multiplex PCR and polymorphism 
analysis of restriction fragments (PCR-RFLP) are commonly used for differentiation of NTM 
species related to lung infections [111, 112]. The real-time PCR assays are advantageous 
because of its rapidity and high sensitivity. Furthermore, the specificity of the real-time PCR 
can be enhanced by combination with HPLC, which is a useful tool to discriminate NTM 
at the species level, although it requires specific equipment and technical expertise [113]. 
Furthermore, multiplex real-time PCR assay combined with melting curve analysis is also 
an accurate, rapid and effective tool for the mycobacterial identification from cultures [114]. 
The commercial form of real-time PCR Light cycler® Mycobacterium detection assay, which 
based on the 16S ribosomal RNA (rRNA), has shown 100% sensitivity and 99% specificity for 
differentiation of MTBC and M. avium from sputum samples [115, 116].
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Several commercial kits, which are based on PCR amplification of selected fragment of 16S 
or 23S rRNA gene or 16S–23S rRNA spacer region, followed by reverse hybridization on 
nitrocellulose membrane strips such as GenoType Mycobacterium CM/AS (Hain Lifescience, 
Nehren, Germany) [117–120] and INNO-LiPA Mycobacteria (LiPA; Innogenetics, Zwijnaarde, 
Belgium) [121, 122] are available for identification of common pathogenic NTM species with 
high sensitivity and specificity. Genus Mycobacterium, MTBC and 16 NTM species are identi-
fied by INNO-LiPA mycobacteria assay, and it is based on the nucleotide variations in the 
16S–23S rRNA spacer region (Figure 4).
Mixed populations easily identified with this assay and fully automated processing of the strips 
is possible using TENDIGO™ and Auto-LiPA 48. GenoType Mycobacterium CM kit identifies 
Figure 4. Location of the different probes on the INNO-LiPA Mycobacteria v2 strip.
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the MTBC and differentiates of 27 clinically relevant NTM, while GenoType Mycobacterium AS 
kit enables the differentiation of 19 additional NTM species (Figures 5 and 6).
Direct sequence analysis of amplified 16S rRNA gene is a promising rapid and accurate 
method for species determination of nontuberculous mycobacteria [123], and in last decades, 
novel NTM species related to pulmonary infections were identified by this technique. In addi-
tion to that, several gene targets, including rpoB gene [124–126], secA1 gene [127] and hsp65 
Figure 5. Location of the different probes on the GenoType Mycobacterium AS  strip.
Figure 6. Location of the different probes on the GenoType Mycobacterium CM strip.
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gene [128], have used for NTM species identification by DNA sequencing. Also, gyrB-based 
microarray [129], mycobacteria mobility shift assay (MMSA) [130], biochip assay system [131] 
and multiplex SNaPshot assay [132] have been proven as rapid detection methods to identify 
closely related mycobacterial species with satisfied level of sensitivity and specificity, which 
may be useful in the diagnosis and effective management of NTM lung disease [129–132].
6. Antimicrobial susceptibility testing for NTM
The laboratory susceptibility testing of pulmonary infective NTM species are based on the 
ATS/IDSA and Clinical and Laboratory Standards Institute (CLSI) guidelines. CLSI has recom-
mended broth microdilution method as the gold standard for laboratories where antimicro-
bial susceptibility testing of NTM is performed [133]. There are no current recommendations 
for a specific method of in vitro susceptibility testing for fastidious NTM species and some 
less commonly isolated NTM species. Validation and quality control should be in place for 
susceptibility testing of antimicrobial agents with all species of NTM. According to the diag-
nostic guidelines for nontuberculous mycobacteria which are recommended by the ATS [22], 
only the Clarithromycin should be tested for susceptibility for new, previously untreated 
MAC isolates and susceptibility testes for other drugs are not recommended. Also, MAC iso-
lates from patients who fail macrolide treatment or prophylaxis regimens should be tested to 
clarithromycin susceptibility. Isolates of M. kansasii that show susceptibility to rifampin will 
also be susceptible to rifabutin. Therefore, previously untreated M. kansasii strains should be 
tested in vitro only to rifampin. The rifampin resistant of M. kansasii isolates should be tested 
against a panel of secondary agents, including rifabutin, ethambutol, isoniazid, clarithromy-
cin, fluoroquinolones, amikacin and sulfonamides. Unless the patient fails treatment after 
several months, M. marinum isolates do not require susceptibility testing.
The in vitro susceptibility patterns of some NTM such as M. kansasii, M. marinum and M. fortuitum  
are closely parallel to the clinical response to therapeutic agents. But, MAC, M. abscessus and 
M. simiae have limited evidences for the correlation between in vitro susceptibility results 
and clinical response in the treatment of pulmonary disease caused by these agents [134]. 
Furthermore, antimicrobial susceptibility patterns of rapidly growing mycobacteria (RGM) 
including isolates of the M. fortuitum group, M. chelonae and M. abscessus provide taxonomical 
value also in addition to the evidence of drug resistance [135].
According to the recent publications, the microplate Alamar Blue assay [136] and tetrazolium 
Microplate Assay [137] have also shown reliable results to the recommended microdilution 
method. However, molecular assays have not yet been able to replace time-consuming cul-
ture-based susceptibility methods in the mycobacteriology laboratory.
7. Treatment of NTM lung infections
After determination of the clinical significance of a NTM species, patient should be treated 
with appropriated antimicrobial regimen. The duration of treatment for most pulmonary 
NTM pathogens is based on treatment recommendations. Frequently encountered species 
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such as MAC and M. kansasii are treated 12 months of negative sputum cultures while on 
therapy. For disseminated disease, treatment duration for most NTM pathogens is the same 
as for disseminated MAC infection.
Treatment recommendations for infrequently encountered NTM are made on the basis of 
only a few reported cases. As recommendations for routine in vitro susceptibility testing 
of NTM isolates are limited, the clinician should use in vitro susceptibility data with an 
appreciation for its limitations. Empiric therapy for suspected NTM lung disease is not 
recommended. Furthermore, there are no widely accepted criteria for choosing patients 
with NTM lung disease for resectional surgery. In generally, surgery could be considered 
based on risk/benefit perspective in case of NTM infections that are more difficult to treat 
medically [22].
7.1. M. avium complex (MAC)
Drug therapy for MAC lung disease should be a combination of several antibiotics (Table 2), 
and the optimal therapeutic regimen has yet to be established [22].
Special recommendations of drug regimens are needed for patients with intolerance to first-
line agents, a macrolide-resistant MAC cases or failed prior drug therapy. The macrolides 
should never be used as monotherapy for treatment of MAC lung disease. The duration of 
the treatment is 12 months of negative sputum cultures while on therapy; hence continuous 
observation of AFB in sputum of the patient is required throughout the treatment [22, 138]. 
The addition of intramuscular streptomycin to standard regimen for the first 3 months of 
treatment for MAC pulmonary disease improves the rate of culture conversion, even though 
clinical response and radiological outcome are not significantly improved. An intermittent 
(3× per week) oral antibiotic regimen should not be used in individuals with severe MAC 
pulmonary disease or in individuals with a history of treatment failure [138].
Major risk factors for macrolide-resistant MAC disease are inappropriate prescription pat-
terns and deviations from the standard treatment due to adverse drug reactions [139]. More 
Drug Initial therapy for nodular/
bronchiectatic disease
Initial therapy for cavitary 
disease
Advance or previously 
treated disease
Macrolide Clarithromycin 1000 mg TIW or 
azithromycin 500–600 mg TIW
Clarithromycin 500*–
1000 mg/d or azithromycin 
250–300 mg/d
Clarithromycin 500*–
1000 mg/d or azithromycin
Ethambutol 25 mg/kg TIW 15 mg/kg/d 15 mg/kg/d
Rifamycin Rifampin 600 mg TIW Rifampin 450*–600 mg/d Rifabutin 150*–300 mg/d or 
rifampin 450*–600 mg/d
IV aminoglycoside None Streptomycin or amikacin 
or none
Streptomycin or amikacin
Notes: IV = intravenous; TIW = three times weekly.*Lower dose for weight 50 kg.
Table 2. Recommended antimicrobial combination [138].
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 effective therapy is essential to treat and prevent macrolide-resistant with MAC lung disease 
[140]. Antibiotic treatment associated with rifampicin, ethambutol and isoniazid or a quino-
lone with streptomycin or amikacin and surgical resection of disease can be used in macro-
lide-resistant MAC diseases [31, 101, 138, 140]. Furthermore, the addition of moxifloxacin can 
improve the outcomes of patients with macrolide-resistant [141]. However, recent study has 
shown that continuation of macrolides or the addition of a new quinolone or injectable ami-
noglycoside to therapy with rifampicin and ethambutol would not improve clinical  outcome 
Species Drug regimen Duration
M. kansasii 
– Rifampicin-sensitive
Rifampicin 600 mg daily + Ethambutol 15 mg/kg daily 
+ Isoniazid 300 mg (with pyridoxine 10 mg) daily or 
Azithromycin 250 mg daily or Clarithromycin 500 mg twice 
daily
12 months after 
culture conversion.
M. malmoense Non-severe disease:
Rifampicin 600 mg daily + Ethambutol 15 mg/kg daily + 
Azithromycin 250 mg daily or Clarithromycin 500 mg twice 
daily
Minimum of 
12 months after 
culture conversion
Severe M. malmoense-pulmonary disease:
Rifampicin 600 mg daily +Ethambutol 15 mg/kg daily + 
Azithromycin 250 mg daily or Clarithromycin 500 mg twice 
daily + consider intravenous amikacin for up to 3 months or 
nebulized amikacin
Minimum of 
12 months after 
culture conversion
M. xenopi Non-severe
Rifampicin 600 mg daily + Ethambutol 15 mg/kg daily + 
Azithromycin 250 mg daily or Clarithromycin 500 mg twice 
daily + Moxifloxacin 400 mg daily or Isoniazid 300 mg (+ 
pyridoxine 10 mg) daily
Minimum of 
12 months after 
culture conversion
Severe
Rifampicin 600 mg daily + Ethambutol 15 mg/kg daily + 
Azithromycin 250 mg daily or Clarithromycin 500 mg twice 
daily + Moxifloxacin 400 mg daily or Isoniazid 300 mg (+ 
pyridoxine 10 mg) daily + consider intravenous amikacin for 
up to 3 months or nebulized amikacin
Minimum of 
12 months after 
culture conversion
M. abscessus Clarithromycin 
sensitive isolates or inducible 
macrolide-resistant cases
Initial phase:
≥1 month iv amikacin 15 mg/kg daily or 3× per week 
+ iv tigecycline 50 mg twice daily and where tolerated 
iv imipenem 1 g twice daily and where tolerated oral 
clarithromycin 500 mg twice daily or oral azithromycin 
250–500 mg daily
Continuation phase:
Nebulized amikacin + oral clarithromycin 500 mg twice daily 
or azithromycin 250–500 mg daily +1–3 of the following 
antibiotics guided by drug susceptibility results + patient 
tolerance: oral clofazimine 50–100 mg daily, oral linezolid 
600 mg daily or twice daily (with pyridoxine 50 mg daily), 
oral minocycline 100 mg twice daily, oral moxifloxacin 400 mg 
daily, oral co-trimoxazole 960 mg twice daily
Minimum of 
12 months after 
culture conversion
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after the emergence of chloramphenicol-resistant MAC [142]. If microbiologic, clinical or 
radiographic improvements are not shown after 6 months of appropriate therapy or achieved 
conversion of sputum to AFB culture negative after 12 months of appropriate therapy, patients 
are considered as treatment failures [22].
In addition to antibiotics, for patients with MAC lung infection, adjunctive therapies may 
also be given. Patients whose disease is predominantly localized to one lung, poor response 
to drug therapy, the development of macrolide-resistant MAC disease or the presence of sig-
nificant disease-related complications such as hemoptysis might be considered for surgery. 
Although adjuvant pulmonary resection is complicated, it provides high level of treatment 
success rate in selected patients [143, 144]. Successful treatment of disseminated MAC in per-
sons with AIDS is based on treatment of both the mycobacterial infection and the HIV infec-
tion. Both clarithromycin and azithromycin have been shown to be effective in combination 
regimens for the treatment of disseminated MAC. But, treatment of these cases may be com-
plicated by adverse drug effects [22, 145].
Recommended treatment regimen for M. kansasii, M. malmoense, M. xenopi and M. abscessus 
is described in Table 3. The treatment for M. abscessus pulmonary disease should comprise 
an initial phase antibiotic regimen followed by a continuation phase antibiotic regimen. 
However, individuals with a history of treatment intolerance or treatment failure should be 
managed in collaboration with a physician experienced in managing NTMPD.
Author details
Chamila Priyangani Adikaram
Address all correspondence to: chamilaadhikaram@yahoo.com
Central Public Health Laboratories, Ministry of Health, Muscat, Oman
Species Drug regimen Duration
M. abscessus Constitutive 
macrolide-resistant cases
Initial phase:
≥1 month iv amikacin 15 mg/kg daily or 3× per week and iv 
tigecycline 50 mg twice daily + where tolerated iv imipenem 
1 g twice daily
Continuation phase:
Nebulised amikacin and 2–4 of the following antibiotics 
guided by drug susceptibility results + patient tolerance: oral 
clofazimine 50–100 mg daily, oral linezolid 600 mg daily or 
twice daily (with pyridoxine 50 mg daily), oral minocycline 
100 mg twice daily, oral moxifloxacin 400 mg daily, oral 
co-trimoxazole 960 mg twice daily
Minimum of 
12 months after 
culture conversion
Note: iv = intravenous.
Table 3. Recommended treatment regimen for M. kansasii, M. malmoense, M. xenopi and M. abscessus pulmonary diseases 
[138].
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